Skip to main content

Table 2 The status of molecular markers in enrolled patients

From: Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy

Disease types

Molecular markers

PTEN loss

PIK3CA mutation/amplification

Gasric cancer

4

1

Colorectal cancer

3

-

Pancreastic cancer

1

-

Cholangiocarcinoma

1

-